Prion diseases are fatal infectious neurodegenerative disorders hypothesised to be caused by misfolding of the prion protein. Following prion infection, the infectious agent is sequestered to and replicates upon follicular dendritic cells (FDC) within lymphoid follicles prior to neuroinvasion. The mechanism of transport of the prion infectious agent from the site of infection to FDC is unknown. One of the postulated routes of transport is the specific migration of antigen presenting cells (APC) to FDC. APC specifically capture antigenic material and transport and present that material to effector cells and FDC in order to generate an appropriate acquired immune response. FDC reside within the B-cell follicle of secondary lymphoid organs. FDC organise and maintain the B-cell follicular structure by secretion of the chemokine CXCL13 which stimulates chemotactic movement of cells which express the CXCR5 receptor, e.g. B cells. Dendritic cells are specialised APC that are commonly characterised by their expression of CD11c. Transport of the prion infectious agent from the site of infection to FDC was observed to be blocked or severely delayed following depletion of CD11c+ cells. To determine whether CD11c+ cells acquire prions and subsequently deliver them to the FDC, the chemokine receptor CXCR5 was depleted from CD11c+ cells using a conditional transgenic mouse model. These mice were characterised for normal lymphoid organogenesis and monitored for their responses to oral infection with either prions or intestinal helminths. Data in this thesis show that the CD11c-mediated depletion of CXCR5 resulted in a delay in peripheral prion pathogenesis after oral exposure and significantly reduced disease susceptibility. These data suggest that efficient prion transport to FDC requires delivery by APC and is potentially mediated by CXCR5 chemotaxis. Following oral exposure to the intestinal helminth (Trichuris muris) CD11c-mediated depletion of CXCR5 prevented the establishment of a protective TH2 response. As a consequence the mice mounted a TH1-dominated response and were unable to clear the infection. These data also confirm that the effective generation of TH2 responses to oral helminth infection also requires APC localisation to B-cell follicles via CXCR5.

Les lymphocytes T CD8+ spécifiques de l'antigène sont impliqués dans la réponse immunitaire adaptative et jouent un rôle essentiel dans la protection de l'hôte contre l'infection par des pathogènes intracellulaires. Cette protection de longue durée dépend de la génération de réponses lymphocytaires T CD8+ mémoires, hautement fonctionnelles en termes de fréquence et de fonctionnalité, après réinfection.Après présentation de l'antigène, une cellule T CD8 naïve subit une forte expansion clonale, générant une population hétérogène de cellules activées qui est dominée, au sommet de l'expansion, par des effecteurs CD8 de courte durée (SLEC). Cette expansion est suivie d'une phase de contraction massive par apoptose. Quelques cellules survivent à cette phase de contraction et finissent par se différencier en cellules mémoire hautement compétentes. Les processus par lesquels et le moment où se différencient les précurseurs de mémoire (MPECs) restent largement inconnus, tout comme les étapes ultérieures de leur maturation en cellules mémoire pleinement fonctionnelles. Les signaux d'aide provenant des cellules T CD4+ sont clairement requis tout au long du processus de maturation des MPEC.Notre équipe a montré que les lymphocytes T CD4+ régulateurs FoxP3+ (Tregs) favorisent la maturation des MPEC en limitant l'exposition à l'IL-2 et en fournissant des signaux inhibiteurs, mais ce n'est probablement qu'une facette de l'aide complexe et multiforme apportée par les cellules T CD4+ au MPEC. Les Tregs agissent sur des MPEC préexistants. Les réponses mémoire B et CD8+ partagent des caractéristiques communes, telles que l'expression du facteur de transcription Bcl-6. Les lymphocytes T CD4+ folliculaires (Tfh) sont les principaux producteurs de la cytokine IL-21. Bien que les mécanismes par lesquels les Tfh induisent l’expression de Bcl-6 dans les cellules B doivent être clarifiés, ils pourraient inclure l’IL-21 et l’interaction CD40-CD40L.Dans ce projet de thèse, nous avons étudié le rôle potentiel des Tfh dans l'initiation de la différenciation mémoire T CD8+, dans des modèles de souris transgéniques permettant une déplétion transitoire et sélective des Tfh, infectées par la bactérie recombinante Listeria monocytogenes-OVA.Nous avons montré que dès 2 jours après l'infection, les MPECs très précoces peuvent être identifiés par l’expression du récepteur de chimiokine CXCR5. Ces précurseurs précoces, qui ont un phénotype effecteur, se développent et migrent temporairement à la jonction des zones T et B, où ils interagissent avec les Tfh puis perdent leur expression CXCR5.Cette interaction avec les Tfh, considérés jusqu'à présent comme des auxiliaires exclusifs des cellules B, est nécessaire pour que les MPECs CD8+ deviennent des cellules mémoire compétentes sensibles à l'IL-21, capables de générer des réponses effectrices secondaires efficaces.Cette étude dévoile les premières étapes cruciales dans la génération de la mémoire CD8+, identifie CXCR5 comme le premier marqueur connu des MPECs CD8+, révèle l’implication fondamentale des Tfh dans le CD4 help et indique une coordination possible, via les Tfh, entre les voies de différentiation mémoire CD8+ et B. Ces résultats peuvent avoir des implications pour la conception du vaccin et de l'immunothérapie. / Antigen-specific CD8 T cells are involved in the adaptive immune response and play a critical role in protecting the host from infection by intracellular pathogens. This long-lasting protection depends on the generation of memory CD8+ T cell responses, which are highly functional in terms of frequency and functionality, after secondary infection.Following antigen activation, a naive CD8 T cell undergoes strong clonal expansion, generating a heterogeneous population of activated cells that is dominated, at the peak of expansion, by short-lived CD8 effectors (SLECs). This expansion is followed by a phase of drastic contraction through massive apoptosis. A few cells survive this contraction phase and eventually become highly competent memory cells. Precisely when and how these memory precursors (MPECs) are generated is largely unknown, and so are the subsequent steps of their maturation into fully functional memory cells. Help signals from CD4+ T cells are clearly required throughout the MPEC maturation process.Our team has previously shown that FoxP3+ regulatory CD4+ T cells (Tregs) favor MPECs maturation by limiting exposure to IL-2 and by providing inhibitory signals, but this is probably only one facet of the complex and multifaceted help provided by CD4+ T cells to MPEC, and Tregs act on pre-existing MPECs.B-cell memory and CD8+ T cell memory share some common features, such as the expression of the transcription factor Bcl-6. Tfh are major producers of the cytokine IL-21. The mechanisms by which Tfh induces Bcl-6 in B-cells need to be clarified, they might include IL-21 and CD40-CD40L.In this PhD project, we have investigated the potential role of Tfh on the initiation of CD8 memory differentiation, in transgenic mice models, allowing transient and selective depletion of Tfh cells, infected by recombinant Listeria monocytogenes-OVA.We have shown that as early as 2 days after infection, very early memory precursors can be identified by their expression of the chemokine receptor CXCR5. These early precursors, which have an effector phenotype, expand and temporarily migrate to the junction of T-cell and B-cell zones, where they interact with follicular CD4 T cells (Tfh) then lose their CXCR5 expression.Remarkably, this interaction with Tfh, hitherto considered as exclusive B-cell helpers, is required for memory precursors to become competent memory cells responsive to IL-21 and capable of mounting efficient cytotoxic secondary effector responses.This study thus unveils critical early steps in the generation of CD8 memory, identifies CXCR5 as the earliest known marker of CD8 memory precursors, reveals a major helper role for Tfh, and points to possible coordination, through Tfh, between the pathways of CD8 and B-cell memory generation. These findings may have implications for vaccine and immunotherapy design.

The germinal centre (GC) response is critical for generating highly effective humoral immune responses and immunological memory that forms the basis of successful immunisation. Control of the output of the GC response requires Follicular regulatory T (Tfr) cells, a subset of Foxp3+ Treg cells located within germinal centres. Tfr cells were first characterised in detail in 2011 and because of this relatively little is known about the exact role of Tfr cells within the GC, and the mechanism/s through which they exert their suppressive function. At the outset of this work, the major barrier to understanding Tfr cell biology was the lack of appropriate tools to study Tfr cells specifically, without affecting Tfh cells or other Treg cell subsets. This thesis set out to develop a strain of mice that specifically lacks Tfr cells. A unique feature of Tfr cells is their CXCR5-dependent localisation within the GC. Therefore, genetic strategies that exclude Treg cells from entering the GC are a rational approach to generating a mouse model that lacks Tfr cells. To this end, I generated a strain of mice that lacks CXCR5 on Foxp3+ Treg cells. These animals show a ~50% reduction in GC localised Tfr cells, and a GC response that is comparable to control animals. These data indicated that redundant mechanisms are involved in Treg cell homing to the GC. I identified CXCR4 as a chemokine receptor that is also highly expressed on Tfr cells, and hypothesised that it may also be involved in Tfr cell localisation to the GC. Surprisingly, simultaneous deletion of both CXCR4 and CXCR5 in Treg cells resulted in a less marked reduction in Tfr cells compared to deletion of CXCR5 alone, suggesting that CXCR4 might be involved in negative regulation of Treg homing to the GC. These data identify both CXCR4 and CXCR5 as key regulators of Tfr cell biology. Bcl6 drives Tfr cell differentiation, but how this transcriptional repressor facilitates commitment to the Tfr cell subset is unknown. I hypothesised that Bcl6 drives Tfr cell differentiation by repressing Tbx21, the transcriptional regulator involved in the differentiation of Th1-like Treg cells. I tested this hypothesis in Bcl6fl/fl CD4cre/+ animals and unexpectedly found that loss of Bcl6 regulates Treg cell differentiation in the absence of immunisation or infection. I have demonstrated that thymic loss of Bcl6 results in an increase in activated effector Treg cells, which occurs very early in life. These data point to a novel role for Bcl6 in preventing early thymic Treg activation, indicating that Bcl6 has a global role in Treg development and differentiation that is not simply limited to Tfr cells.

Submitted by Ubirajara Cruz (ubirajara.cruz@gmail.com) on 2017-03-28T12:27:53Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Tese_Fernando_Bandeira.pdf: 1564177 bytes, checksum: 8d086e34d835408a590bd8a69d5aa73a (MD5) / Approved for entry into archive by Aline Batista (alinehb.ufpel@gmail.com) on 2017-03-28T20:58:42Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Tese_Fernando_Bandeira.pdf: 1564177 bytes, checksum: 8d086e34d835408a590bd8a69d5aa73a (MD5) / Made available in DSpace on 2017-03-28T20:58:42Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Tese_Fernando_Bandeira.pdf: 1564177 bytes, checksum: 8d086e34d835408a590bd8a69d5aa73a (MD5) Previous issue date: 2015-02-25 / Sem bolsa / A mastite bovina é um problema sanitário mundial, com medidas de tratamento e prevenção insatisfatórias. Paralelamente, vem crescendo o interesse no uso de própolis como alternativa para tratamento das mastites, sendo ainda, objeto de estudos com finalidade de uso como adjuvante. Até o momento, porém, não foi descrito seu uso em vacinas para controle da mastite bovina. A importância do gênero Staphylococcus como agente da enfermidade é bem documentada, crescendo a necessidade de identificação da espécie do agente etiológico. A pesquisa identificou 12,6% de estafilococos coagulase positiva em mastites subclínicas na região sul do Brasil, sendo que S. aureus estando presente em 17,6% dos animais pesquisados. Dentre os isolados coagulase positiva, a frequência de S. aureus foi de 85,7%, a de S. intermedius foi de 8,5% e de S. hyicus foi 5,8%. A bactéria S. aureus utiliza vários fatores de patogenicidade para causar a infecção no hospedeiro. Foi pesquisado em bases de dados, as informações recentes sobre os principais produtos expressos e forma de atuação. Descreveu-se os principais mecanismos ligados a penetração do micro-organismo na glândula mamária, os processos que medeiam a formação do biofilme e suas estratégias de sobrevivência as respostas do hospedeiro, resultando em processos que muitas vezes tornam-se crônicos. Finalmente, é desejável a utilização de uma vacina eficiente para colaborar no controle da mastite, e dessa forma foi proposta a utilização de uma bacterina contendo extrato hidro-alcoólico de própolis verde na formulação. Comparou-se o seu efeito com uma formulação sem adição de própolis, vacina comercial e PBS esterilizado, em um trabalho conduzido em 63 bovinos. De forma semelhante, com os mesmos grupos de tratamento, mas com a adição de um grupo que recebeu apenas o extrato hidroalcoólico de própolis verde, foi conduzida uma pesquisa em 30 camundongos BALB/c. A pesquisa de anticorpos IgG em bovinos, demonstrou que tanto o tratamento contendo extrato hidroalcóolico de própolis verde quanto a bacterina sem própolis apresentaram resultados semelhantes, superiores aos tratamentos utilizando a vacina comercial e PBS, sendo que nos mesmos tratamentos, foi observada uma resposta com característica humoral inicialmente, tendendo a celular ao longo do experimento. Nos bovinos, a expressão relativa de RNAm para INF-γ, IL-2 e CXCR5 foi elevada para o grupo que recebeu a bacterina contendo extrato hidroalcoólico de própolis verde. Os resultados do teste de ELISA em camundongos, foram semelhantes aos encontrados para os bovinos. O grupo que recebeu apenas o extrato hidroalcoólico de própolis verde sem nenhuma combinação bacteriana, demonstrou resposta com predominância de IgG1 ao longo da pesquisa, semelhante aos grupos de vacina comercial e PBS. No modelo murino, a vacina comercial apresentou índices maiores de expressão de RNAm para as citocinas pesquisadas em esplenócitos. Os resultados obtidos sugerem que a bacterina contendo extrato hidroalcoólico de própolis verde apresenta potencial para atuar como ferramenta no controle da mastite bovina. / Bovine mastitis is a global health problem and many scientific advances have occurred, but the treatment and prevention of disease with existing techniques do not present satisfactory results. Similarly, there is growing interest in the use of propolis as an alternative for treatment of mastitis, also being the object of studies in order to use as an adjuvant, although so far it has not been described their use in vaccines for the control of bovine mastitis. The importance of Staphylococcus gender as disease agent is well documented, growing need for species identification of the etiologic agent. In a survey of coagulase-positive staphylococci in subclinical mastitis in southern Brazil, was finding its presence in 12.6% of cases with S. aureus was present in 17.6% of animal researched. Among the considered coagulase positive S. aureus is 85.7%, 8.5%, were S. intermedius and 5.8% were identified as S. hyicus. For the S. aureus penetrate, multiply and keep the host uses multiple pathogenic factors. Was researched in the literature to-date information on the main mechanisms expressed by the bacteria and how they operate, alone or integrated to ensure the penetration of micro-organism in the mammary gland, the processes that mediate the formation of biofilms and their coping strategies the host responses, their internalization in the cells and its continuation mechanisms, resulting in processes that often become chronic. To assist in the control of mastitis, is desirable the use of an effective vaccine and thus has been proposed the use of a bacterin containing hydroalcoholic extract of green propolis in the formulation is desirable, being compared to a similar bacterin without propolis, commercial vaccine and sterile PBS on a work carried out on 63 bovines. Similarly, with the same treatment groups and the addition of a group that received only the hydroalcoholic extract of propolis, a study was conducted on 30 BALB/c mice. The research of IgG antibodies in bovines showed that both treatment containing hydroalcoholic extract of propolis as the bacterin without propolis showed similar results and superior to commercial and PBS treatments, and the same treatment, we observed initially characteristic a humoral response with tending to cellular during throughout the experiment. In bovines, the relative expression of mRNA for INF-γ, IL-2 and CXCR5 was raised to the group receiving bacterin containing hidroalcoholic extract of green propolis. The ELISA results were similar to those of bovine in BALB/c still with the group that received only the the alcoholic extract of propolis without any bacterial combination, behaving similarly commercial and PBS, and the response was predominantly IgG1 to during the research. In the murine model, the commercial vaccine showed higher levels of mRNA expression for the studied cytokines. The results indicate that the bacterin containing alcoholic extract of propolis has the potential to act as a tool in the control of bovine mastitis in the target especie, requiring minor adjustments and a job to prove the efficiency in a challenge.

CAR-T-Zell-Therapie ist eine vielversprechende neuartige Behandlungsform für Patienten mit aggressiven B-Zell Non-Hodgkin-Lymphomen (B-NHL). In dieser Arbeit wurde die anti-CXCR5 CAR-T-Zell-Therapie als Alternative zur anti-CD19 CAR-T-Zell-Therapie für die Behandlung von reifen B-NHLs untersucht. CXCR5 ist ein B-Zell-homing Rezeptor, der von reifen B Zellen und follikulären T-Helferzellen (TFH Zellen) exprimiert wird. TFH Zellen wurden als tumor-unterstützend in chronisch lymphatischer Leukämie (CLL) und im follikulären Lymphom (FL) beschrieben. Dieses Expressionsmuster erlaubt es, auf einzigartige Weise zeitgleich die malignen Zellen und die tumorunterstützende Mikroumgebung mithilfe von CAR-T-Zell-Therapie gerichtet gegen einen Chemokinrezeptor anzugreifen. Die wichtigsten Ergebnisse dieser Arbeit waren, dass (1) die anti-CXCR5 CAR T-Zellen zielgerichtet CXCR5 positive reife B-NHL Zelllinien und Patientenproben in vitro eliminierten und eine starke anti-Tumor Reaktivität in einem immundefizienten Xenotransplantationsmausmodell zeigten, (2) die anti-CXCR5 CAR T-Zellen zielgerichtet die tumorunterstützenden TFH Zellen in CLL und FL Patientenproben in vitro erkannten und dass (3) CXCR5 ein sicheres Expressionsprofil zeigte. CXCR5 war stark und häufig auf B-NHL exprimiert und die Expression auf gesundem Gewebe war auf lymphoide Zellen beschränkt. Zusammenfassend lässt sich sagen, dass die anti-CXCR5 CAR-T-Zell-Therapie eine neue Behandlungsmöglichkeit für Patienten mit reifen B-NHL darstellt, indem durch die anti-CXCR5 CAR-T Zellen sowohl der Tumor als auch ein Anteil der tumorunterstützende Mikroumgebung eliminiert werden. Im zweiten Teil der Arbeit wurde das Eμ-Tcl1 murine CLL Lymphommodell genutzt um die Auswirkung der Lymphomentwicklung auf die CXCR5+ T Zellen zu untersuchen. Mittels RNA-Einzelzell-Sequenzierung konnte ein profunder Einfluss des Lymphomwachstums auf das T Zell-Kompartiment der Mäuse, denen Eμ-Tcl1 Zellen gespritzt wurden, gezeigt werden. / CAR T cell therapy is a promising new treatment option for patients suffering from aggressive B non-Hodgkin lymphomas (NHLs). In CAR T cell therapy, patient-derived T cells are genetically modified to express a chimeric receptor commonly directed towards a surface antigen expressed by neoplastic cells. In this thesis, anti-CXCR5 CAR T cell therapy was investigated as an alternative to anti-CD19 CAR T cell therapy for the treatment of mature B-NHLs. CXCR5 is a B cell homing receptor expressed by mature B cells and follicular helper T (TFH) cells. TFH cells were described to support the tumor cells in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). This expression pattern allows simultaneous targeting of the malignant cells and the tumor-supporting microenvironment by CAR T cell therapy against a chemokine receptor in an unprecedented manner. Main findings included that (1) anti-CXCR5 CAR T cells targeted specifically CXCR5 expressing mature B-NHL cell lines and patient samples in vitro and showed strong in vivo anti-tumor reactivity in an immunodeficient xenograft mouse model, (2) anti-CXCR5 CAR T cells targeted tumor-supportive TFH cells derived from CLL and FL patient samples in vitro and (3) CXCR5 showed a safe expression profile. CXCR5 was strongly and frequently expressed by B-NHLs and its expression on healthy tissue was restricted to lymphoid cells. In summary, anti-CXCR5 CAR T cell therapy presents a novel treatment option for patients suffering from mature B-NHLs by eliminating the tumor and part of the tumor-supportive microenvironment. The second part of the project, the Eμ-Tcl1 murine lymphoma model, which mimics human CLL, was used to study the impact of lymphomagenesis on CXCR5+ T cells. Using single cell RNA sequencing, a profound influence of lymphoma growth on the T cell compartment in Eμ-Tcl1 tumor-challenged mice could be shown.